Such a move could threaten the considerable preventive goods portfolio of Gilead, which offers a range of drugs in the segment, including popular human immunodeficiency virus (HIV) prevention ...

Gilead Sciences Inc. (GILD) Gilead Sciences is a biopharmaceutical company that develops treatments for HIV/AIDS, hepatitis C, liver disease, hematology/oncology and inflammation.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said ...

LONDON (AP) — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus’ transmission. In a ...

Foster City, Calif., July 25, 2025 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted ...

Drugmaker Gilead has said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates — mostly in Africa, Southeast Asia and the Caribbean.

Endorsement for Gilead’s PrEP injection The CHMP has also provided a positive opinion on Gilead Sciences' HIV pre-exposure prophylaxis (PrEP) Yeytuo (lenacapavir), a twice-a-year subcutaneous ...

Gilead Sciences said a key European regulatory committee recommended accelerated approval of its twice-yearly lenacapavir injection for HIV prevention. Gilead on Friday said the recommendation by ...

Gilead was recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences ...

Needham upgraded Gilead stock to buy today. The analyst sees billion-dollar potential in Gilead's Yeztugo drug for preventing HIV. Gilead stock looked cheap before the upgrade. It could be an even ...

How Gilead is helping innovate HIV prevention, removing stigma and empowering Black women. By Spenser Mestel This story was created in paid partnership with Gilead Sciences. Pre-exposure ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate settlement with Gilead Sciences, Inc. over an illegal kickback scheme to ...